LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma

Trial Profile

LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Nintedanib (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Acronyms LUME-Meso
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Mature Phase 2 overall survival and updated progression free survival results (n=87) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results from this trial published in a Boehringer Ingelheim Media Release.
    • 05 Jun 2017 Updated phase II results from this trial were presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) according to a Boehringer Ingelheim media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top